CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma

被引：10

作者：

Chu, Bin ^{[1
]}

Bao, Li ^{[1
]}

Wang, Yutong ^{[1
]}

Lu, Minqiu ^{[1
]}

Shi, Lei ^{[1
]}

Gao, Shan ^{[1
]}

Fang, Lijuan ^{[1
]}

Xiang, Qiuqing ^{[1
]}

Liu, Xi ^{[1
]}

机构：

[1] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China

来源：

CLINICAL IMMUNOLOGY | 2020年 / 213卷

基金：

北京市自然科学基金;

关键词：

Multiple myeloma; CD27; antigen; Overall survival; Cytogenetic; Gene mutation; MULTIPARAMETRIC FLOW-CYTOMETRY; MINIMAL RESIDUAL DISEASE; CLINICAL-SIGNIFICANCE; CEREBLON EXPRESSION; SURVIVAL; IDENTIFICATION; PREDICTION; MUTATIONS; CONSENSUS; SPECTRUM;

D O I：

10.1016/j.clim.2020.108363

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To investigate the role of CD27 in multiple myeloma(MM), bone marrow samples from 165 newly diagnosed MM were analysed by flow cytometry. CD27- group (n = 93) had higher level of plasma cell proportion (37.00% vs 22.50%, p < .05), beta 2-MG (5.42 vs 3.20 mg/L, p < .05), calcium (2.45 vs 2.28 mmol/L, p < .05),higher percentage of ISS stage III (49.46% vs 22.22%, p < .05) and patients with >= 2 high-risk cytogenetics (24.73% vs 15.28%, p < .05) than CD27+ group (n = 72). After 4 cycles of chemotherapy, the overall response rate in CD27- group were lower than CD27+ group (56.67% vs 73.02%, p < .05). After a median follow-up of 18 months, progression-free survival was significantly shorter in CD27- group than in CD27+ group (22 vs 40 months, p < .05), so was overall survival (median OS not reached, p < .05). Gene sequencing showed more adverse mutations in CD27- group than CD27+ group.

引用

页数：8

共 33 条

[1] CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma [J].

Alaterre, Elina ;

Raimbault, Sebastien ;

Goldschmidt, Hartmut ;

Bouhya, Salahedine ;

Requirand, Guilhem ;

Robert, Nicolas ;

Boireau, Stephanie ;

Seckinger, Anja ;

Hose, Dirk ;

Klein, Bernard ;

Moreaux, Jerome .

ONCOTARGET, 2017, 8 (58) :98931-98944

[2] Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines [J].

Anderson, Kenneth C. ;

Alsina, Melissa ;

Atanackovic, Djordje ;

Biermann, J. Sybil ;

Chandler, Jason C. ;

Costello, Caitlin ;

Djulbegovic, Benjamin ;

Fung, Henry C. ;

Gasparetto, Cristina ;

Godby, Kelly ;

Hofmeister, Craig ;

Holmberg, Leona ;

Holstein, Sarah ;

Huff, Carol Ann ;

Kassim, Adetola ;

Krishnan, Amrita Y. ;

Kumar, Shaji K. ;

Liedtke, Michaela ;

Lunning, Matthew ;

Raje, Noopur ;

Reu, Frederic J. ;

Singhal, Seema ;

Somlo, George ;

Stockerl-Goldstein, Keith ;

Treon, Steven P. ;

Weber, Donna ;

Yahalom, Joachim ;

Shead, Dorothy A. ;

Kumar, Rashmi .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (04) :389-400

[3] Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials [J].

Arana, P. ;

Paiva, B. ;

Cedena, M-T ;

Puig, N. ;

Cordon, L. ;

Vidriales, M-B ;

Gutierrez, N. C. ;

Chiodi, F. ;

Burgos, L. ;

Anglada, L-L ;

Martinez-Lopez, J. ;

Hernandez, M-T ;

Teruel, A-I ;

Gironella, M. ;

Echeveste, M-A ;

Rosinol, L. ;

Martinez, R. ;

Oriol, A. ;

De la Rubia, J. ;

Orfao, A. ;

Blade, J. ;

Lahuerta, J-J ;

Mateos, M-V ;

San Miguel, J-F .

LEUKEMIA, 2018, 32 (04) :971-978

[4] Immunophenotypic Characterization and Quantification of Neoplastic Bone Marrow Plasma Cells by Multiparametric Flow Cytometry and Its Clinical Significance in Korean Myeloma Patients [J].

Cho, Young-Uk ;

Park, Chan-Jeoung ;

Park, Seo-Jin ;

Chi, Hyun-Sook ;

Jang, Seongsoo ;

Park, Sang Hyuk ;

Seo, Eul-Ju ;

Yoon, Dok Hyun ;

Lee, Jung-Hee ;

Suh, Cheolwon .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (04) :542-549

[5] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[6] High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes [J].

Hu, Bei ;

Thall, Peter ;

Milton, Denai R. ;

Sasaki, Koji ;

Bashir, Qaiser ;

Shah, Nina ;

Patel, Krina ;

Popat, Uday ;

Hosing, Chitra ;

Nieto, Yago ;

Lin, Pei ;

Delgado, Ruby ;

Jorgensen, Jeffrey ;

Manasanch, Elisabet ;

Weber, Donna ;

Thomas, Sheeba ;

Orlowski, Robert Z. ;

Champlin, Richard ;

Qazilbash, Muzaffar H. .

LEUKEMIA & LYMPHOMA, 2019, 60 (02) :442-452

[7]

Katayama Y., 2003, BRIT J HAEMATOL, V120, P556

[8] Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients [J].

Kortuem, K. M. ;

Braggio, E. ;

Bruins, L. ;

Barrio, S. ;

Shi, C. S. ;

Zhu, Y. X. ;

Tibes, R. ;

Viswanatha, D. ;

Votruba, P. ;

Ahmann, G. ;

Fonseca, R. ;

Jedlowski, P. ;

Schlam, I. ;

Kumar, S. ;

Bergsagel, P. L. ;

Stewart, A. K. .

BLOOD CANCER JOURNAL, 2016, 6

[9] Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes [J].

Kortum, K. Martin ;

Mai, Elias K. ;

Hanafiah, Nur H. ;

Shi, Chang-Xi ;

Zhu, Yuan-Xiao ;

Bruins, Laura ;

Barrio, Santiago ;

Jedlowski, Patrick ;

Merz, Maximilian ;

Xu, Jing ;

Stewart, Robert A. ;

Andrulis, Mindaugas ;

Jauch, Anna ;

Hillengass, Jens ;

Goldschmidt, Hartmut ;

Bergsagel, P. Leif ;

Braggio, Esteban ;

Stewart, A. Keith ;

Raab, Marc S. .

BLOOD, 2016, 128 (09) :1226-1233

[10] Lack of CD27 in myeloma delineates different presentation and outcome [J].

Moreau, P ;

Robillard, N ;

Jégo, G ;

Pellat, C ;

Le Gouill, S ;

Thoumi, S ;

Avet-Loiseau, H ;

Harousseau, JL ;

Bataille, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (02) :168-170

← 1 2 3 4 →